Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic...
-
Upload
aubrey-booker -
Category
Documents
-
view
212 -
download
0
Transcript of Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic...
![Page 1: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/1.jpg)
Swain 23 Oct. 021
Embol-X
Clinical Reviewers
Wolf Sapirstein M.D.
Julie Swain M.D.
(Cardiothoracic Surgery)
![Page 2: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/2.jpg)
Swain 23 Oct. 022
Study Design
• Randomized, multicenter
• Control 644 patients, Filter 645 patients
• Control arm = patients without filter
• Interim data analysis at 50% of patients
![Page 3: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/3.jpg)
Swain 23 Oct. 023
Investigational Plan
• “If the hypothesis tests performed at the interim are statistically significant, indicating emboli capture and equivalent safety, the study will be terminated”
• The study was continued to completion to attempt to show safety superiority (which was not shown)
![Page 4: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/4.jpg)
Swain 23 Oct. 024
Inclusion/Exclusion Criteria
• Elective operations• Isolated CAB or valve• Age >60• Total 24 exclusion criteria
– Neurological deficit – Hx major stroke (as defined by a clinical history of
fixed, focal neurological deficit attributable to stroke) – Redo operations– Renal failure on dialysis
![Page 5: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/5.jpg)
Swain 23 Oct. 025
Neurological Evaluation(Gross Neurologic Testing)
• History, Physical Exam
• NIH Stroke Score
• No neuropsychological testing
![Page 6: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/6.jpg)
Swain 23 Oct. 026
Endpoints
• Efficacy: >75% of filters trap at least one particle
• Composite Primary Safety: 12 items (Not worse than control group with an equivalency delta of 5%)
• Secondary Safety: Aortic Injury (not part of composite safety endpoint)
![Page 7: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/7.jpg)
Swain 23 Oct. 027
Patient Demographics
• No statistical differences in baseline characteristics between treatment and control group
• Treatment group:– 73% male– 91% Caucasian– Average age 71 years
![Page 8: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/8.jpg)
Swain 23 Oct. 028
Types of operations
CABG
AVR
MVR/R
8%6%
84%
![Page 9: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/9.jpg)
Swain 23 Oct. 029
Composite Safety Endpoint(12 clinical events)
• DeathNeurological• Stroke• TIA• Non-metabolic comaRenal• Creatinine >2.0 or increased 50% (non-dialysis)• DialysisGastrointestinal• Bleeding requiring transfusion• Pancreatitis• Cholecystitis• Mesenteric ischemiaCardiac• Q-wave MI• Non Q-wave MILimb threatening periph. embolism
Diminished pulseAltered pallorPain
![Page 10: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/10.jpg)
Swain 23 Oct. 0210
Number of Particles Trapped
0
10
20
30
40
50
60
% filters
0 1-5 6-10 11-20 >20
Maximum number trapped = 25 (38 in roll-in)Total number of particles embolized unknown
Mean 5.6 particles/filter
![Page 11: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/11.jpg)
Swain 23 Oct. 0211
Selected Events
0123456789
10
Death Stroke ARF(dialysis)
Q wave MI AorticInjury
Filter
Control
%patients
*
* P < .001
![Page 12: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/12.jpg)
Swain 23 Oct. 0212
Manipulation-Related Aortic Injury
0
4
8
12
FilterRollIn Filter
Control
% patients
*
* p<0.001 vs control
7/78 42/456
9/454
![Page 13: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/13.jpg)
Swain 23 Oct. 0213
Manipulation-Related Aortic Injury
• Occurred in 9.2% of filter patients (42/456 patients)
• 3 filter patients required aortic repair
• Study protocol follow-up: 30 day or hospital discharge, whichever occurred first (median follow-up 7.0 days)
• Post hoc designed telephone follow-up of 43/49 aortic injury patients (roll in + randomized), 18/49 had > 1 year follow-up
• No apparent training effect
• Not associated with increase in Adverse Events
![Page 14: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/14.jpg)
Swain 23 Oct. 0214
Post-Hoc Data Analysis
• These analyses were not planned prospectively in the investigational plan
• Statistical treatment of post hoc analyses is not straight-forwardNominal p-values do not account for
multiplicityNo way to know how much adjustment should
be applied when judging "significance"
![Page 15: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/15.jpg)
Swain 23 Oct. 0215
Selected Adverse Events(Higgins score >5)
0
2
4
6
8
Death Stroke ARF (dialysis) Q wave MI
Filter
Control
%patients
p = N.S. for all points
4
5
8
6
4
6
5
3
![Page 16: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/16.jpg)
Swain 23 Oct. 0216
Summary
Embol-X Control p value
Trapped at least
one particle
97%
Composite safety
endpoint
17.1% 18.9% n.s.
Individual safety events n.s.
Aortic injuries 9.2% 2.0% <.001
![Page 17: Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)](https://reader035.fdocuments.in/reader035/viewer/2022072017/56649f065503460f94c1ba5b/html5/thumbnails/17.jpg)
Swain 23 Oct. 0217
Conclusions
The filter traps particles
A correlation with clinical improvement was not shown
Additional concerns were raised by the occurrence of aortic injuries